NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$179.79
$179.79
50-Day Range
N/A
52-Week Range
$39.82
$179.99
Volume
N/A
Average Volume
1.65 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KITE stock logo

About (KITE) Stock (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

KITE Stock News Headlines

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Greenup's Kite Day wild and windy
Go fly a kite ... for mental health
See More Headlines
Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2017
Today
4/26/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:KITE
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Arie S. Belldegrun
    Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson
    Chief Financial Officer
  • Cynthia M. Butitta
    Chief Operating Officer
  • David Chang M.D. Ph.D.
    Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim
    Executive Vice President - Business Development
  • Timothy L. Moore
    Executive Vice President - Technical Operations
  • Christine Cassiano
    Senior Vice President - Corporate Communications and Investor Relations

  • Bio & Compensation - 
  • Jian Irish Ph.D.
    Senior Vice President - Supply Chain

  • Bio & Compensation - 
  • Jeffrey Wiezorek M.D.
    Senior Vice President - Clinical Development
  • Shawn Cline Tomasello
    Chief Commercial Officer

KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) announced its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) EPS for the quarter, topping the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company earned $4.90 million during the quarter, compared to the consensus estimate of $5.74 million. The business's revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.54) EPS.

What other stocks do shareholders of (KITE) own?
This page (NASDAQ:KITE) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners